Early Notification and Brand Change Montelukast Tablets
As advised via PHARMAC Tender Results of 29 March there is to be a change in the listing and future sole supply of Montelukast Tablets.
New listing from 1 August 2019
Montelukast Mylan Tab 4 mg 28 blister pack Pharmacode TBA Schedule price $4.25
Montelukast Mylan Tab 5 mg 28 blister pack Pharmacode TBA Schedule price $4.25
Montelukast Mylan Tab 10 mg 28 blister pack Pharmacode TBA Schedule price $3.95
Incumbent brand to be DELISTED 1 January 2020.
Montelukast-Apo Tab 4 mg 28 blister Pharmacode 2511797 Schedule price $5.25
Montelukast-Apo Tab 5mg 28 blister Pharmacode 2511800 Schedule price $5.50
Montelukast-Apo Tab 10 mg 28 blister Pharmacode 2511789 Schedule price $5.65
Montelukast-Accord Tab 10 mg 28 blister Section 29 Pharmacode 2548321 Schedule price $5.65
Reference pricing will not apply.
HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 January 2020.
Brand Switch Fee not in notification.
As of the date of this notification ProPharma / PWR cannot accept Montelukast-Apo Tab (all strengths) for credit under any circumstances.
From 1 August 2019 community pharmacies dispensing Montelukast Tablets will need to support patients changing to the new brand and manage stock during the transition.
We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted where practical
Due to price change for Montelukast Mylan Tab 10mg to a Low Cost Medicine we are unable to set up automatic replacement. We will set up automatic replacements for both 4 mg and 5 mg.
You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 January 2020. Failure to do so may prove costly.
Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.
ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 January 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.
Together we can make this a seamless and painless transition.
We thank you in anticipation of your ongoing support.